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Michael Salerno, MD, PHDSEE PAGE 991H eart failure (HF) is a major cause ofmorbidity and mortality and is a leadingreason for hospitalization in older pa-
tients. The economic impact of HF is astronomical,
exceeding $37 billion in the United States alone
(1). Heart failure with preserved ejection fraction
(HFpEF) accounts for nearly one-half of all cases of
HF with a similar mortality to that of systolic heart
failure (SHF) (2). Although the mortality rate for
SHF has steadily declined over the past few decades
with improved medical therapy, the mortality rate
for HFpEF has remained high; in addition, despite
numerous therapeutic trials, there are no proven
therapies for HFpEF. The diagnosis of HFpEF is often
clinically challenging, relying on a combination of
clinical symptoms, echocardiographic criteria, and
biomarkers such as brain natriuretic peptide, which
all have potential limitations (3).
Cardiac magnetic resonance (CMR) is well estab-
lished for the evaluation of focal myocardial ﬁbrosis
using the late gadolinium enhancement technique but
cannot detect diffuse myocardial ﬁbrosis. There has
been growing interest in using T1 mapping techniques
to assess diffuse myocardial ﬁbrosis (4). Multiple
studies in patients with HF undergoing myocardial
biopsy have shown an inverse correlation between the
degree of histological ﬁbrosis and the T1 relaxation
time measured 10 min after gadolinium contrast in-
jection (5,6). However, the T1 of the myocardium is a
function not only of the amount of ﬁbrosis but also of
contrast dose, clearance rate, and time after injection
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conﬁned to the extracellular space. Thus, T1 mapping
techniques can be used to quantify the extracellular
volume (ECV). By measuring T1 before and after either
a bolus or equilibrium infusion of gadolinium, the
partition coefﬁcient and ECV can be measured (7,8).
Validation of the correlation between ECV and histo-
logical evidence of myocardial ﬁbrosis has been
assessed in aortic stenosis, hypertrophic cardiomyop-
athy, dilated cardiomyopathy, and congenital heart
disease (7,8). Increased ECV has been shown to be
associated with adverse cardiovascular events (9).
However, to date, there has been limited application of
ECV assessment to patients with HFpEF.In this issue of iJACC, Su et al. (10) evaluated the
relationship between ECV measured by T1 mapping
to diastolic dysfunction as assessed by cine CMR in
control subjects, patients with SHF, and patients with
HFpEF (10). The authors used a variant of the modi-
ﬁed Look-Locker inversion recovery (MOLLI) pulse
sequence, which should be robust to variations in
heart rate. Imaging was performed before and 10 min
after gadolinium injection using the bolus method.
ECV was quantiﬁed with care taken to exclude areas
of focal myocardial ﬁbrosis.
Themain ﬁnding of the study was that patients with
heart failure, both those with SHF and those with
HFpEF, had increased ECV as compared with control
subjects with the highest ECV in the cohort with SHF.
Similarly, peak ﬁlling rates were signiﬁcantly reduced
in patients with SHF and reduced to a lesser extent in
patients with HFpEF. Interestingly, ECV was corre-
lated with peak ﬁlling rate in the HFpEF group but not
in the control subjects or those with SHF. The pre-
contrast T1 time (native T1) was not signiﬁcantly
different between the groups. This is not entirely un-
expected because native T1 is sensitive to water in
both the intracellular and extracellular compartments
of the myocardium. Post-contrast T1 times were
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999shortest in the SHF group followed by the HFpEF
group and longest in healthy subjects, which is
explained by the accumulation of the gadolinium
contrast agent in the extracellular space. A reduction
in post-contrast T1 times has also been shown in
patients with HFpEF and was associated with either
hospitalization for HF or cardiac death (11).
Increasing ECV was associated with reduction in
ejection fraction and a decrease in the peak ﬁlling
rate. This suggests that ECV is sensitive to subtle
changes in systolic and diastolic function, because
ﬁbrosis likely contributes to both of these compo-
nents of cardiac function in patients with HFpEF.
Overall, this study was well conducted; however,
there are a few limitations. The authors only used
volume-time curve analysis to assess diastolic func-
tion. This concept has been validated in nuclear
studies and duplicated with CMR, but these tech-
niques are much less frequently used than established
echocardiographic parameters (12). Furthermore, CMR
has multiple other techniques for evaluation of dia-
stolic function that were not studied. It would have
been interesting to see if measures of diastolic func-
tional grade by echocardiography or E/e0 measure-
ments correlated with ECV in patients with HFpEF or
SHF. Second, post-contrast imaging was only per-
formed at 10 min post-contrast. The bolus technique
requires an assumption of “equilibrium” of contrast
concentrations in the myocardium and blood pool
and this may take longer than 10 min, particularly in
patients with increased ECV. Furthermore, the use of
only a single post-contrast time precludes assess-
ment of the validity of this assumption (13). Also,
although the diastolic functional parameters corre-
lated with ECV in HFpEF, it is somewhat surprising to
see a lack of correlation among patients with SHF
because these patients also have diastolic dysfunc-
tion. It is possible that this could be due to both the
presence and effects of both diffuse and focal ﬁbrosis
in patients with SHF.
ECV mapping to detect diffuse ﬁbrosis and inﬁl-
tration has been a topic of intense research; however,there are multiple important issues that still need to
be addressed by the ﬁeld for widespread application.
Although the ﬁeld appears to be converging on a few
acquisition strategies, there is still a lack of consensus
about the optimal technique. Small biases in T1 caused
by T2, off-resonance, and magnetization transfer ef-
fects limit direct comparison between different tech-
niques and ﬁeld strengths. ECV is also inﬂuenced by
contrast agent concentration and the type of gado-
linium contrast agent, because ECV measured by CMR
is the effective volume of distribution of the contrast
agent. Thus, care should be taken when comparing
ECV measurements using different techniques. ECV
relies on multiple T1 measurements, so inaccuracies
in the quantiﬁcation of T1 can propagate into the
determination of ECV. Additionally, greater study will
be required to determine if ECV can be used as a
diagnostic tool in the management of individual pa-
tients. Further standardization and study will be
required to prove diagnostic and prognostic utility,
and the ﬁrst consensus document on this topic was
recently published (14).
The measurement of ECV could have important
implications in patients with HFpEF. Elevation of
ECV in patients with shortness of breath could pro-
vide additional evidence of HFpEF in patients with
borderline echocardiography or biomarker ﬁndings.
ECV could better deﬁne a phenotype of patients with
HFpEF who may beneﬁt from novel antiﬁbrotic
therapies. Finally, ECV could be used to track the
therapeutic response of a drug or potentially serve
as a surrogate marker for clinical trials. ECV mapping
will likely be an important tool for helping us see
previously unseen aspects of the clinically chal-
lenging pathology of HFpEF.
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